CRB-913 - (CANYON-1)

October 22, 2026: Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) said late-breaking data from the Phase 1b CANYON-1 study of CRB-913 in obesity will be presented at Obesity Week 2026. The poster, titled “Efficacy, Safety, and Tolerability of CRB-913 in the Ph1b CANYON-1 Study,” is scheduled for November 15, 2026, from 2:30–3:30 p.m. ET at the Gaylord National Resort & Convention Center in National Harbor, Maryland, with Harold Bays, M.D. as presenter. The release does not provide study results, only that efficacy, safety, and tolerability data will be presented. Corbus also identifies CRB-913 as an orally delivered, highly peripherally restricted CB1 inverse agonist for obesity.